Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial-Reference-Cited by-同舟云学术

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial

Published:2008-11 Issue:11 Volume:19 Page:1837-1841
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Pestalozzi B.C.,Francis P.,Quinaux E.,Dolci S.,Azambuja E.,Gelber R.D.,Viale G.,Balil A.,Andersson M.,Nordenskjöld B.,Gnant M.,Gutierrez J.,Láng I.,Crown J.P.A.,Piccart-Gebhart M.

Funder

National Health and Medical Research Council

Swiss Group for Clinical Cancer Research

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/11/1837/507086/mdn385.pdf

Reference14 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists Collaborative Group;Lancet,2005

2. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007;Goldhirsch;Ann Oncol.,2007